greeksoup/ stock research
Stock research / United States / TLSI / Insiders

TriSalus Life Sciences, Inc. insider trading

In twelve months insiders at TriSalus Life Sciences bought $3.6M and sold $140K on the open market; none of the 18 sales was under a plan set in advance.

Bought on the open market$3.6M12 purchases
Sold on the open market$140K18 sales
Sales set in advanceNoneall 18 chosen by the insider
Pay taken in stock50 by own choice
New to this? How to read this page
  1. Insiders are the people who run the company: officers, directors and owners of 10% or more. They must report a trade on Form 4 within two business days.
  2. A purchase on the open market is the strongest sign: the insider spent their own money.
  3. A sale under a trading plan (Rule 10b5-1) says little: its dates were fixed months before. Sales outside a plan say more, but insiders sell for many reasons, such as taxes or a house.
  4. Grants, option exercises and shares held back for tax are left out.
  5. What is a Form 4? · Form 4 codes

What kind of trades

12 purchases worth $3.6M against 18 sales worth $140K; no sale was under a plan set in advance.

Purchasebought with their own money
Pay in stock, own choiceowed cash, chose shares
Sale outside a planthe insider picked the day
Sale under a plandates fixed months before
Says littlecompany plans, board pay, cash units
Bought
12 open market5
Sold
18 outside a plan

Every Form 4 line of the last twelve months, counted by kind. The grades come from the filing itself: whether the insider paid cash, whether a plan set the date, whether pay was taken in stock by choice.

Insider trades on the share price

last twelve months

33 marks over twelve months, each in its grade: solid for the stronger signs, hollow or grey for the ones that say little.

PurchasePay in stock, own choiceSale outside a planSale under a planSays little

The blue line is the daily close over twelve months. Each mark is one insider's trades on one day, on that day's price, sized by dollar value. Solid marks are the stronger signs; hollow and grey marks say little. Hover or tap a mark for who, how much and why.

Trades worth a closer look

A purchase stands out when two or more of these hold: a senior insider, several insiders buying within 90 days, a fall of 10% or more in the three months before, or over $1 million. A sale outside a plan is judged the same way. These are the Feed's rules.

Who traded

dollars, twelve months

10 insiders traded. The most: Stansky Michael P, purchase $3.0M.

One row per insider, sold to the left and bought to the right, split by grade: the paler part of a bar is the part that says little.

How it compares

every company on the site

Open-market sales, twelve months

Open-market purchases, twelve months

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every Form 4 line

    Purchase: bought on the open market with their own moneyTook pay in stock, own choice: owed cash, chose shares instead; a softer signSale: sold on the open market, not under a plan set in advanceSale, trading plan: under a Rule 10b5-1 plan set up months before, so the date was fixed in advanceGrey lines: plan purchases, pay in stock taken by the whole board or under a company plan, and units paid in cash; they say little about the insider's own view
    TradedInsiderRoleTypeSharesPriceValueFiling
    5 October 2026Cox Bryan F.Chief of ResearchSaleafter a 2% rise over three months · 42% below its one-year high296$4.39$1,299Form 4
    5 October 2026Marshak RichardChief Commercial OfficerSaleafter a 2% rise over three months · 42% below its one-year high325$4.39$1,427Form 4
    5 October 2026Stevens JenniferChief Regulatory OfficerSaleafter a 2% rise over three months · 42% below its one-year high316$4.39$1,387Form 4
    15 May 2026Marshak RichardChief Commercial OfficerSaleafter a 45% fall over three months · 64% below its one-year high543$2.67$1,450Form 4
    15 May 2026Wahlstrom MatsDirectorPurchaseafter a 45% fall over three months · 64% below its one-year high60,000$2.53$151,800Form 4
    15 May 2026Stansky Michael PDirectorPurchaseafter a 45% fall over three months · 64% below its one-year high410,000$2.50$1.0 millionForm 4
    15 May 2026Stansky Michael P, by Skyview Investments LLCDirectorPurchaseafter a 45% fall over three months · 64% below its one-year high200,000$2.50$500,000Form 4
    15 May 2026Szela Mary TCEO and PresidentPurchaseafter a 45% fall over three months · 64% below its one-year high39,682$2.59$102,776Form 4
    15 May 2026Patience DavidChief Financial OfficerPurchaseafter a 45% fall over three months · 64% below its one-year high7,100$2.43$17,253Form 4
    15 May 2026Gordon Gary B.DirectorPurchaseafter a 45% fall over three months · 64% below its one-year high10,000$2.46$24,600Form 4
    14 May 2026Wahlstrom MatsDirectorTook pay in stockone of 5 insiders the same day34,226n/an/aForm 4
    14 May 2026Gordon Gary B.DirectorTook pay in stockone of 5 insiders the same day24,553n/an/aForm 4
    14 May 2026Matlin David JDirectorTook pay in stockone of 5 insiders the same day23,065n/an/aForm 4
    14 May 2026Valle WilliamDirectorTook pay in stockone of 5 insiders the same day24,553n/an/aForm 4
    14 May 2026Stansky Michael PDirectorTook pay in stockone of 5 insiders the same day20,089n/an/aForm 4
    17 March 2026Szela Mary TCEO and PresidentSaleafter a 46% fall over three months · 46% below its one-year high15,944$3.85$61,384Form 4
    16 March 2026Devlin JodiChief of Clinical OperationsSaleafter a 44% fall over three months · 45% below its one-year high273$4.12$1,125Form 4
    16 March 2026Cox Bryan F.Chief of ResearchSaleafter a 44% fall over three months · 45% below its one-year high579$4.12$2,385Form 4
    16 March 2026Marshak RichardChief Commercial OfficerSaleafter a 44% fall over three months · 45% below its one-year high419$4.12$1,726Form 4
    16 March 2026Stevens JenniferChief Regulatory OfficerSaleafter a 44% fall over three months · 45% below its one-year high774$4.12$3,189Form 4
    12 March 2026Devlin JodiChief of Clinical OperationsSaleafter a 45% fall over three months · 45% below its one-year high1,772$4.09$7,247Form 4
    12 March 2026Cox Bryan F.Chief of ResearchSaleafter a 45% fall over three months · 45% below its one-year high1,467$4.09$6,000Form 4
    12 March 2026Marshak RichardChief Commercial OfficerSaleafter a 45% fall over three months · 45% below its one-year high1,589$4.09$6,499Form 4
    12 March 2026Stevens JenniferChief Regulatory OfficerSaleafter a 45% fall over three months · 45% below its one-year high1,552$4.09$6,348Form 4
    11 March 2026Devlin JodiChief of Clinical OperationsSaleafter a 43% fall over three months · 45% below its one-year high1,162$4.13$4,799Form 4
    11 March 2026Cox Bryan F.Chief of ResearchSaleafter a 43% fall over three months · 45% below its one-year high1,138$4.13$4,700Form 4
    11 March 2026Marshak RichardChief Commercial OfficerSaleafter a 43% fall over three months · 45% below its one-year high1,449$4.13$5,984Form 4
    11 March 2026Stevens JenniferChief Regulatory OfficerSaleafter a 43% fall over three months · 45% below its one-year high1,204$4.13$4,973Form 4
    11 March 2026Szela Mary TCEO and PresidentSaleafter a 43% fall over three months · 45% below its one-year high4,358$4.13$17,999Form 4
    23 February 2026Patience DavidChief Financial OfficerPurchaseafter a 10% fall over three months · 33% below its one-year high3,657$4.10$14,994Form 4
    23 February 2026Gordon Gary B.DirectorPurchaseafter a 10% fall over three months · 33% below its one-year high9,756$4.10$40,000Form 4
    23 February 2026Valle WilliamDirectorPurchaseafter a 10% fall over three months · 33% below its one-year high30,487$4.10$124,997Form 4
    23 February 2026Szela Mary TCEO and PresidentPurchaseafter a 10% fall over three months · 33% below its one-year high30,487$4.10$124,997Form 4
    23 February 2026Stansky Michael PDirectorPurchaseafter a 10% fall over three months · 33% below its one-year high243,900$4.10$999,990Form 4
    23 February 2026Stansky Michael P, by LLCDirectorPurchaseafter a 10% fall over three months · 33% below its one-year high117,198$4.10$480,512Form 4
    A filing with several lines appears once per line.
    Read morePay taken in stock by the insider's own choice has the filing's footnote, word for word, in the note under it; for the others, hold the pointer on the type. An award filed at no price shows n/a.